Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (21554)	5/3/1999 7:07:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

blankmind....the market for the treatment of Female SD can be bigger than Viagra. The treatment of PE can also be as large as Viagra. The trick is what portion of the marketplace Vivus can capture. The female SD cream/gel can capture the greater portion of the market vrs an oral pill. A PE drug using the same method of use as MUSE will have a more difficult time in capturing a majority of the market if there is an oral pill to compete with that works well. If no Oral pill competes with VVUS PE solution then VVUS will own the PE market like they did the ED market in 1997.